Startups channel feed – Endpoints News

Startups channel feed

The human element: A biotech upstart hopes to carve a path around faulty animal models

6 years ago

Allievex launches with Pappas cash and rare disease drug from BioMarin

6 years ago

Armed with Langer tech and $50M, Verseau hails new checkpoint drugs unleashing macrophages against cancer

6 years ago

Sean Parker helps create a CRISPRed cell therapy 2.0 play — and he’s got a high-profile set of leaders on the team

6 years ago

San Diego upstart debuts discovery engine that puts a twist to protein degradation

6 years ago

Cyteir nets $40M for rad synthetic lethality platform — throwing another monkey wrench at cell repair

6 years ago

Boehringer Ingelheim-backed Abalos tosses hat into packed oncolytic virus ring

6 years ago

'We're ripe': Cygnal draws the curtain on Flagship's latest bet on exoneural biology — and $65M in cash

6 years ago

Ness Bermingham looks to lead the wave of RNA editing at new Atlas upstart Korro Bio

6 years ago

Antibody research graduates from a top Oxford lab into the biotech world — with $34M to fund R&D work

6 years ago

Aeovian Pharmaceuticals brings in $37 million in mTOR play

6 years ago

San Francisco biotech has its heart in heart failure — and $92M in the bank

6 years ago

ARC-T? Alternative CAR-T startup bags $85M for clinical quest to redirect 'blind hunter' T cells

6 years ago

Deerfield bets on New York City, blueprints $635M biotech hub in midtown Manhattan

6 years ago

Meissa obtains $30M Series A from Morningside to test synthetic biology approach to 'elusive' RSV vaccines

6 years ago

Boehringer Ingelheim backs Max Planck spinout in taking a shot at tough class of cancer targets

6 years ago

Startup EPM launches, high off cannabinoid acid innovation

6 years ago

New Flagship biotech wants to unleash your genome

6 years ago

Jeff Kindler's Centrexion renews bid to make public debut

6 years ago

'A fourth revolution in cancer therapies': ARCH-backed Boundless Bio flashes big check, makes bigger promises in debut

6 years ago

Biotech boards burdened: Bridging the success gap

6 years ago

Preclinical cancer biotech IGM Biosciences sets stage for upsized $175M IPO

6 years ago

BenevolentAI's latest financing could halve its $2B valuation — and that has Woodford watchers worried

6 years ago

Star founders, investigators huddle around new Boston accelerator spotlighting young entrepreneurs

6 years ago

First page Previous page 55 56 575859 60 61 Next page Last page